Work

C3-targeting siRNA Combined with Oseltamivir Alleviates Inflammation and Lung Injury in H1N1-Infected Mice

Year: 2026
Type: preprint
Abstract: Influenza A H1N1 infection can trigger severe inflammatory responses that contribute to pulmonary tissue injury and disease progression. Aberrant complement activation is presumed to contribute to these pathological changes. Nevertheless, it remains unclear whether complement C3 serves as a shared upstream regulatory node linking inflammation and hemolytic injury. In this study, we established an H1N1-infected mouse model to dynamically monitor changes in inflammation, hemolysis and complement-related parameters throughout infection. We evaluated the C3-silencing efficacy of RG002, a liver-targeted siRNA against complement C3, as well as the therapeutic efficacy of RG002 combined with oseltamivir against H1N1 infection. Our results showed that H1N1 infection induced prominent inflammatory responses and alterations in peripheral blood cell parameters, accompanied by pulmonary histopathological injury in mice. Hepatic C3 expression and complement activity were simultaneously and markedly elevated. RG002 suppressed C3 expression in a dose-and time-dependent manner and reduced complement-mediated erythrocyte lysis in serum. In vivo therapeutic experiments demonstrated that on the basis of viral replication suppression achieved by oseltamivir, combination treatment with RG002 inhibited excessive complement activation. This combined regimen reduced pro-inflammatory cytokine levels, attenuated pulmonary histopathological injury, and improved selected peripheral blood cell parameters. Notably the low-dose RG002 combination group exhibited superior performance across multiple evaluation indices, suggesting that the degree of C3 suppression is preferable to influence therapeutic effucaty. Collectively, our findings implicate complement C3 in the inflammatory pathology associated with H1N1 infection and demonstrate the therapeutic potential of C3-targeting siRNA as an adjunct to antiviral treatment. This study provides experimental evidence supporting the combination of antiviral therapy and controlled complement modulation as a potential host-directed therapeutic strategy for severe influenza. Graphical Abstract H1N1 influenza virus infection triggers pulmonary inflammation and excessive complement activation, exacerbating lung injury. Here, we present a dual-targeted therapeutic strategy integrating antiviral treatment with host complement modulation. Oseltamivir suppresses viral replication, while RG002, a C3-targeting siRNA, silences hepatic C3 expression to attenuate complement overactivation. Their combined administration alleviates pulmonary inflammation and tissue injury, reduces proinflammatory cytokine levels, improves biochemical indicators, and decreases hepatic C3 expression and serum complement activity. This strategy offers a promising therapeutic approach for influenza-associated lung injury.
Language: English
Subfield: Epidemiology
Field: Medicine
Open Access status: green
OpenAlex ID: W7234760139
Cites: 40
Cited by:
Related to: 10